193 related articles for article (PubMed ID: 12117601)
1. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease.
Murray TK; Messenger MJ; Ward MA; Woodhouse S; Osborne DJ; Duty S; O'Neill MJ
Pharmacol Biochem Behav; 2002 Sep; 73(2):455-66. PubMed ID: 12117601
[TBL] [Abstract][Full Text] [Related]
2. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat.
Dawson L; Chadha A; Megalou M; Duty S
Br J Pharmacol; 2000 Feb; 129(3):541-6. PubMed ID: 10711353
[TBL] [Abstract][Full Text] [Related]
3. Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.
Austin PJ; Betts MJ; Broadstock M; O'Neill MJ; Mitchell SN; Duty S
Br J Pharmacol; 2010 Aug; 160(7):1741-53. PubMed ID: 20649576
[TBL] [Abstract][Full Text] [Related]
4. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
Xue YQ; Zhao LR; Guo WP; Duan WM
Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.
Bové J; Serrats J; Mengod G; Cortés R; Tolosa E; Marin C
Exp Brain Res; 2005 Sep; 165(3):362-74. PubMed ID: 15968457
[TBL] [Abstract][Full Text] [Related]
6. Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies.
Ahmad M; Yousuf S; Khan MB; Hoda MN; Ahmad AS; Ansari MA; Ishrat T; Agrawal AK; Islam F
Pharmacol Biochem Behav; 2006 Jan; 83(1):150-60. PubMed ID: 16500697
[TBL] [Abstract][Full Text] [Related]
7. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.
Abuirmeileh A; Lever R; Kingsbury AE; Lees AJ; Locke IC; Knight RA; Chowdrey HS; Biggs CS; Whitton PS
Eur J Neurosci; 2007 Jul; 26(2):417-23. PubMed ID: 17650114
[TBL] [Abstract][Full Text] [Related]
8. LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia.
Bond A; Ragumoorthy N; Monn JA; Hicks CA; Ward MA; Lodge D; O'Neill MJ
Neurosci Lett; 1999 Oct; 273(3):191-4. PubMed ID: 10515191
[TBL] [Abstract][Full Text] [Related]
9. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
[TBL] [Abstract][Full Text] [Related]
10. The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Johnson KA; Jones CK; Tantawy MN; Bubser M; Marvanova M; Ansari MS; Baldwin RM; Conn PJ; Niswender CM
Neuropharmacology; 2013 Mar; 66():187-95. PubMed ID: 22546615
[TBL] [Abstract][Full Text] [Related]
11. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
12. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors.
Popoli P; Pèzzola A; Torvinen M; Reggio R; Pintor A; Scarchilli L; Fuxe K; Ferré S
Neuropsychopharmacology; 2001 Oct; 25(4):505-13. PubMed ID: 11557164
[TBL] [Abstract][Full Text] [Related]
13. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
[TBL] [Abstract][Full Text] [Related]
14. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.
Rosenblad C; Martinez-Serrano A; Björklund A
Neuroscience; 1998 Jan; 82(1):129-37. PubMed ID: 9483509
[TBL] [Abstract][Full Text] [Related]
15. Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268.
Cartmell J; Monn JA; Schoepp DD
Naunyn Schmiedebergs Arch Pharmacol; 2000 Jan; 361(1):39-46. PubMed ID: 10651145
[TBL] [Abstract][Full Text] [Related]
16. Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model.
Park HJ; Lim S; Joo WS; Yin CS; Lee HS; Lee HJ; Seo JC; Leem K; Son YS; Kim YJ; Kim CJ; Kim YS; Chung JH
Exp Neurol; 2003 Mar; 180(1):93-8. PubMed ID: 12668152
[TBL] [Abstract][Full Text] [Related]
17. Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
Broadstock M; Austin PJ; Betts MJ; Duty S
Br J Pharmacol; 2012 Feb; 165(4b):1034-45. PubMed ID: 21627638
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
19. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.
Lapchak PA; Miller PJ; Collins F; Jiao S
Neuroscience; 1997 May; 78(1):61-72. PubMed ID: 9135089
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.
Vernon AC; Palmer S; Datla KP; Zbarsky V; Croucher MJ; Dexter DT
Eur J Neurosci; 2005 Oct; 22(7):1799-806. PubMed ID: 16197521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
